European Society for Medical Oncology (ESMO)

This phase 2 study aimed to assess the efficacy and safety of a combination of pembrolizumab, plinabulin, and docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who have developed resistance to immunotherapy. Read More ›

The second interim analysis of overall survival from the BEAT-SC trial assessed bevacizumab for its effectiveness and safety in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) in Japan and China. Read More ›

This study evaluated real-world treatments and outcomes of limited disease small cell lung cancer (SCLC) using the Canadian SCLC Database (CASCADE). Read More ›

An ongoing, open-label, single-arm phase 2 study (IFCT-1904) evaluated patients with untreated BRAF V600E-mutant non-small cell lung cancer (NSCLC) who received encorafenib plus binimetinib. Read More ›

Data from phase 2 trials involving lurbinectedin and irinotecan have been analyzed for patients with relapsed small cell lung cancer (SCLC) who have had a chemotherapy-free interval of >30 days. Read More ›

A pooled analysis of 5-year clinical outcomes from 2 early-phase trials, NEOSTAR and CA209-159, showed promising long-term clinical effectiveness in patients with resectable non-small cell lung cancer (NSCLC). Read More ›

Interim results from a phase 1/2 study that evaluated the clinical safety and efficacy of HPN328, a trispecific, delta-like canonical Notch ligand 3 (DLL3)–targeting T-cell engager, in patients with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NENs) was presented at the 2023 ESMO annual meeting. Read More ›

Based on improvements in survival outcomes with a PD-1/PD-L1 inhibitor in combination with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC), a nonrandomized, single-center, phase 2 study (LungMate-005; NCT04539977) was conducted to explore the clinical safety and efficacy of neoadjuvant PD-L1 inhibitor TQB2450 plus chemotherapy induction therapy followed by surgery or radiotherapy in patients with limited-stage small-cell lung cancer (LS-SCLC). Read More ›

The majority of patients with small cell lung cancer (SCLC) present with extensive-stage disease, which is associated with poor prognosis. Read More ›

Atezolizumab plus carboplatin/etoposide is indicated for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) based on results of the pivotal phase 3 IMpower133 trial. Read More ›